Abstract: A tactile communication tool for transforming a user input command into an audio output signal is provided. The tool presents a user with a housing, a plurality of buttons, a sound processing unit with a speaker, and an overlay set with a plurality of tactually discernable non-Braille characters or tactually discernable non-Braille images embossed upon it. The plurality of tactually discernable non-Braille images characters or tactually discernable non-Braille images can be positioned over the plurality of buttons such that when one of the buttons is pressed by a user, the user input command is processed, and an audio output signal is generated. The tool could also be used for providing input to a computer system. The overlay set could also be a plurality of individual tactile overlay keys.

Abstract: A tactile communication tool for transforming a user input command into an audio output signal is provided. The tool presents a user with a housing, a plurality of buttons, a sound processing unit with a speaker, and an overlay set with a plurality of tactually discernable non-Braille characters or tactually discernable non-Braille images embossed upon it. The plurality of tactually discernable non-Braille images characters or tactually discernable non-Braille images can be positioned over the plurality of buttons such that when one of the buttons is pressed by a user, the user input command is processed, and an audio output signal is generated. The tool could also be used for providing input to a computer system. The overlay set could also be a plurality of individual tactile overlay keys.

Abstract: An adapter set for converting a visual communication tool to a tactile communication tool is provided. The visual communication tool presents a user with a plurality of actuatable visual cues to be actuated by a user thereby causing rendering of a word or phrase. The adapter set includes a plurality of tactile overlays. Each tactile overlay is positionable over and securable to a corresponding actuatable visual cue where the tactile overlay has a tactile pattern that represents the corresponding visual cue. Characteristically, the tactile pattern being recognizable by touch.

Abstract: A full-core biopsy device comprises an outer cannula hub with an outer cannula coupled at a proximal end to the hub, the outer cannula with a tissue slicing feature defined at the distal tip configured for cutting tissue. The device further comprises an inner member hub and an inner member coaxially disposed within the outer cannula and coupled at a proximal end to the inner member hub. The inner member includes a tubular body, an inner member tip at an opposite distal end thereof and an elongated scoop portion defined between the tubular body and tip. The distal ends of the outer cannula and the scoop portion of the inner member define cooperating forcing cone features.

Abstract: A full-core biopsy device comprises an outer cannula hub with an outer cannula coupled at a proximal end to the hub, the outer cannula with a tissue slicing feature defined at the distal tip configured for cutting tissue. The device further comprises an inner member hub and an inner member coaxially disposed within the outer cannula and coupled at a proximal end to the inner member hub. The inner member includes a tubular body, an inner member tip at an opposite distal end thereof and an elongated scoop portion defined between the tubular body and tip. The distal ends of the outer cannula and the scoop portion of the inner member define cooperating forcing cone features.

Abstract: Disclosed are novel, halogen-free flame-retardants derived from 9,10-Dihydro-9-Oxa-10-Phosphaphenantrene-10-oxide (DOPO) of the structure below: This invention also relates to the use of the halogen free DOPO derived compositions as flame-retardants in polymers, and a process of preparing the above compounds by reacting a formula A compound with a formula B compound:

Abstract: The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.

Abstract: The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Abstract: The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Abstract: The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Abstract: The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.

Abstract: The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Abstract: The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

Abstract: The invention is directed to novel heteroaryl peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis and related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted heteroaryl peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

Abstract: The applicants have discovered that consuming milk-based protein, carbohydrate, Vitamin D, calcium, and CLA in combination and in the relative concentrations disclosed herein results in a beneficial synergistic impact on body composition. It is believed that each component is directly or indirectly utilized in metabolic pathways which alter body composition in beneficial ways that would not be realized if one or more of the components were delivered separately and/or in concentrations other than those disclosed herein. Conventional food and beverages do not deliver the combination of these components in concentrations that maximize the synergistic potential. In certain exemplary embodiments, the composition described herein delivers, per 8 ounce serving, about 5 to 20 grams of milk-protein, about 5 to 26 grams of carbohydrate, about 98 to 1000 IU of Vitamin D, about 350-600 mg of calcium, and about 0.5 to 5 grams of conjugated linoleic acid to a consumer.

Abstract: The invention is directed to novel heteroaryl peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis and related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted heteroaryl peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

Abstract: The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.